Abstract:Sustained-release bupropion is commonly used for the symptomatic relief of depressive disorders and as an adjuvant in smoking cessation therapy. The frequency of adverse reactions with bupropion has been estimated to be more than 1%. Hypersensitivity reactions to bupropion are fairly common and include rare cases of serum sickness-like reaction. Here we report a case of bupropion hydrochloride induced serum sickness-like reaction. Complete resolution of symptoms was achieved on discontinuing bupropion and inst… Show more
“…Low-grade inflammation is believed to be involved in the poor responsiveness to regular antidepressants 1 . Moreover, despite the repeatedly mentioned anti-inflammatory effects, some controversies are reported regarding bupropion action including the development of some inflammatory abnormalities such as type 1 hypersensitivity reactions (erythema multiformeis) and serum sickness-like reaction 26,27 . Moreover, Eller et al observed elevated levels of IL-8 in response to bupropion 28 .…”
There are accumulating reports regarding poor response to the common
antidepressant therapy. Antidepressant resistance has often been
associated with activation of the inflammatory system. Accordingly,
major depressive disorder (MDD) patients displaying inflammation prior
to the treatment are less responsive to antidepressants. We hypothesized
that the inefficacy of antidepressant therapy in some patients could be
due to the drugs’ inflammatory mode of action that remained overshadowed
by their substantial therapeutic value. Bupropion is a common-used
antidepressant that is prescribed for seasonal affective disorders and
smoking cessation as well. Nevertheless, there are some reports
regarding inflammation induction and depressive behavior exacerbation in
response to bupropion. Here, we put a spot on bupropion and investigate
the alterations of innate and adaptive immunity cytokines and the
influence on immune signaling pathways. Therefore, we treated
LPS-stimulated human peripheral mononuclear cells (PBMCs) with different
doses of bupropion. Pro-/ anti-inflammatory cytokines (TNF-ɑ, IL-1ß,
IL-17, and IL-10) on both transcriptional and translational levels are
assessed as well as the involvement of the JAK2 /STAT3, TLR2, and TLR4
signaling in this process. Bupropion decreased IL-17A, TNF-ɑ, and IL-1ß
protein levels in the cultures. Nonetheless, the results regarding the
target genes expression were controversial. Surprisingly, IL-1ß, TNF-ɑ,
and IL-17A genes expression increased following bupropion treatment.
TLR2, TLR4, JAK2, and STAT3 gene expression also rose in response to
bupropion. Our findings suggest that bupropion possesses
pro-inflammatory properties especially at concentrations of 50 and 100
and would rather be co-administrated with anti-inflammatory agents at
least in patients with inflammatory conditions.
“…Low-grade inflammation is believed to be involved in the poor responsiveness to regular antidepressants 1 . Moreover, despite the repeatedly mentioned anti-inflammatory effects, some controversies are reported regarding bupropion action including the development of some inflammatory abnormalities such as type 1 hypersensitivity reactions (erythema multiformeis) and serum sickness-like reaction 26,27 . Moreover, Eller et al observed elevated levels of IL-8 in response to bupropion 28 .…”
There are accumulating reports regarding poor response to the common
antidepressant therapy. Antidepressant resistance has often been
associated with activation of the inflammatory system. Accordingly,
major depressive disorder (MDD) patients displaying inflammation prior
to the treatment are less responsive to antidepressants. We hypothesized
that the inefficacy of antidepressant therapy in some patients could be
due to the drugs’ inflammatory mode of action that remained overshadowed
by their substantial therapeutic value. Bupropion is a common-used
antidepressant that is prescribed for seasonal affective disorders and
smoking cessation as well. Nevertheless, there are some reports
regarding inflammation induction and depressive behavior exacerbation in
response to bupropion. Here, we put a spot on bupropion and investigate
the alterations of innate and adaptive immunity cytokines and the
influence on immune signaling pathways. Therefore, we treated
LPS-stimulated human peripheral mononuclear cells (PBMCs) with different
doses of bupropion. Pro-/ anti-inflammatory cytokines (TNF-ɑ, IL-1ß,
IL-17, and IL-10) on both transcriptional and translational levels are
assessed as well as the involvement of the JAK2 /STAT3, TLR2, and TLR4
signaling in this process. Bupropion decreased IL-17A, TNF-ɑ, and IL-1ß
protein levels in the cultures. Nonetheless, the results regarding the
target genes expression were controversial. Surprisingly, IL-1ß, TNF-ɑ,
and IL-17A genes expression increased following bupropion treatment.
TLR2, TLR4, JAK2, and STAT3 gene expression also rose in response to
bupropion. Our findings suggest that bupropion possesses
pro-inflammatory properties especially at concentrations of 50 and 100
and would rather be co-administrated with anti-inflammatory agents at
least in patients with inflammatory conditions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.